Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Alexion Pharmaceuticals is a biotechnology company working to develop and deliver life-changing drug therapies for patients with serious and life- threatening medical conditions. Alexion is engaged in the discovery and development of therapeutic products aimed at treating patients with a wide array of severe disease states, including hematologic diseases, cancer, and autoimmune disorders. Alexion’s lead product candidate, SolirisÔ (eculizumab), is currently undergoing evaluation in several clinical development programs, including for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Under the Special Protocol Assessment (SPA) process, the FDA has agreed to the design of protocols for the two phase III trials of SolirisÔ (eculizumab) in PNH ( www.alexionpharm.com )
Alexion Pharmaceuticals , Inc.
352 Knotter Drive
Cheshire, Connecticut 06410
USA
Tel: (203) 272-2596
Fax: (203) 271-8190